Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.50 is 92% above its 5-year average of -30.50, near the high end of its 5-year range (-70.50–0.93).
192.40% below its 12-month average of -0.85.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.34.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 35 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:37:13.983Z. Historical observations retain their original dates. Historical series through 2025-05-09.
EARNINGS PER SHARE (EPS)
-2.50
EARNINGS PER SHARE (EPS) AVG TTM
-0.85
EARNINGS PER SHARE (EPS) AVG 3Y
-11.13
EARNINGS PER SHARE (EPS) AVG 5Y
-30.50
EARNINGS PER SHARE (EPS) AVG 10Y
-248.59
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-192.40%
CURRENT VS 3Y AVG
+77.53%
CURRENT VS 5Y AVG
+91.80%
CURRENT VS 10Y AVG
+98.99%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kiora Pharmaceuticals, Inc.
Market Cap
$11.12M
Earnings Per Share (EPS)
-2.50
TTM Avg
-0.85
3Y Avg
-11.13
5Y Avg
-30.50
Market Cap
$11.19M
Earnings Per Share (EPS)
-1.70
TTM Avg
-1.75
3Y Avg
-3.38
5Y Avg
-5.94
Market Cap
$11.06M
Earnings Per Share (EPS)
-2.45
TTM Avg
-3.00
3Y Avg
-4.04
5Y Avg
-6.77
Market Cap
$11.22M
Earnings Per Share (EPS)
-4.43
TTM Avg
-27.97
3Y Avg
-98701.49
5Y Avg
-256134.32
Market Cap
$11.01M
Earnings Per Share (EPS)
-3.20
TTM Avg
-7.58
3Y Avg
-60.73
5Y Avg
-69.78
Market Cap
$11.27M
Earnings Per Share (EPS)
-0.73
TTM Avg
-0.46
3Y Avg
-0.46
5Y Avg
-0.46
Market Cap
$11.29M
Earnings Per Share (EPS)
-1.34
TTM Avg
-1.18
3Y Avg
-34.71
5Y Avg
-76.23
Market Cap
$10.92M
Earnings Per Share (EPS)
-16.53
TTM Avg
-14.84
3Y Avg
-116.30
5Y Avg
-277.16
Market Cap
$10.80M
Earnings Per Share (EPS)
N/A
TTM Avg
-68.10
3Y Avg
-34.05
5Y Avg
-22.70
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kiora Pharmaceuticals, Inc. (KPRX) | $11.12M | -2.50 | -0.85 | -11.13 | -30.50 |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.19M | -1.70 | -1.75 | -3.38 | -5.94 |
| Pluri Inc. (PLUR)vs › | $11.06M | -2.45 | -3.00 | -4.04 | -6.77 |
| Cerenome, Inc. (CNSY)vs › | $11.22M | -4.43 | -27.97 | -98701.49 | -256134.32 |
| BioVie Inc. (BIVI)vs › | $11.01M | -3.20 | -7.58 | -60.73 | -69.78 |
| Caring Brands, Inc. (CABR)vs › | $11.27M | -0.73 | -0.46 | -0.46 | -0.46 |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.29M | -1.34 | -1.18 | -34.71 | -76.23 |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.92M | -16.53 | -14.84 | -116.30 | -277.16 |
| Polyrizon Ltd. (PLRZ)vs › | $10.80M | N/A | -68.10 | -34.05 | -22.70 |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.65M | -1.64 | -2.15 | -4.34 | -5.45 |
Trailing EPS (TTM)
$-2.50
Forward EPS (Est.)
$-1.67
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.64 |
| 2024-12-31 | 0.93 |
| 2023-12-31 | -24.25 |
| 2022-12-31 | -18.55 |
| 2021-12-31 | -68.00 |
| 2020-12-31 | -70.50 |
| 2019-12-31 | -89.24 |
| 2018-12-31 | -182.81 |
| 2017-12-31 | -556.17 |
| 2016-12-31 | -906.30 |
| 2015-12-31 | -817.01 |
| 2014-12-31 | -153.35 |
| 2013-12-31 | -436.38 |
| 2012-12-31 | -678.75 |
